These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19850587)

  • 1. FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.
    Zenáhlíková Z; Kvasnicka J; Kudrnová Z; Sudrová M; Brzezková R; Mazoch J; Malíková I; Vyborny J; Erhart D; Pecen L
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):584-90. PubMed ID: 19850587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
    Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
    J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
    Eriksson BI; Borris L; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Kälebo P;
    J Thromb Haemost; 2006 Jan; 4(1):121-8. PubMed ID: 16409461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coagulation tests in septic surgical patients].
    Oberhofer D; Kucisec-Tepes N; Skok J; Vucić N; Cala K
    Acta Med Croatica; 2004; 58(5):389-94. PubMed ID: 15756805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
    Akanmu AS; Nnodu OE; Giwa SO; Salako LA; Akinsete I; Adebule GT; Adekoya-Cole TO; Odunubi OO
    Afr J Med Med Sci; 2004 Dec; 33(4):335-40. PubMed ID: 15977441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
    Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
    Meier TR; Myers DD; Wrobleski SK; Zajkowski PJ; Hawley AE; Bedard PW; Ballard NE; Londy FJ; Kaila N; Vlasuk GP; Schaub RG; Wakefield TW
    Thromb Haemost; 2008 Feb; 99(2):343-51. PubMed ID: 18278184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
    Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
    J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
    Al Otair HA; Abdel Gader AG; Khurshid SM; Alzeer AH; Al Momen AK; Al Shaikh M; Al Gahtani F; Al Aseri ZA; Abdelrazik HA
    Turk J Haematol; 2016 Jun; 33(2):112-8. PubMed ID: 26377606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.